Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2011

View Archived Issues

Bristol-Myers Squibb claims new tyrosine-protein kinase BTK inhibitors

New formylpeptide FPR2/ALX receptor agonists disclosed

Siena Biotech patents new inhibitors of hedgehog signaling

Vitae Pharmaceuticals describes novel 11-beta-HSD1 inhibitors

V-5 immunitor appears safe and effective in phase IIb tuberculosis trial

Study clarifies effect of amantadine on PD-associated dyskinesia

Clinical trial verifies mechanism of antisense oligonucleotide LY-2181308

New ligands claimed of nicotinic acetylcholine alpha7/alpha4beta2 receptors

FDA extends label for Actemra

First-in-human study evaluates multikinase inhibitor 4SC-203

Xoma reports interim phase II data on XOMA-052 in type 2 diabetes

Cyclacel provides overview of 2010 and outlines objectives for 2011

Amgen and Xencor to jointly develop XmAb-5871

DBV Technologies raises funds to support development of Viaskin Peanut

Pharmasset reports on two programs in HCV infection

Apaziquone enters Japanese phase I trial in bladder cancer

Teva Pharma adds women's health portfolio with acquisition of Theramex

Russian government clears Cel-Sci 's phase III Multikine trial in head and neck cancer

Spectrum Pharma and Viropro sign agreement for development of rituximab biosimilar

Opexa prepares pivotal phase III trial of Tovaxin in MS

Ziopharm Oncology and Intrexon partner to develop DNA-based oncology therapeutics

Inhibition of HSP 90 is efficacious in MET-amplified tumor cells

Ardea's phase IIb RDEA-594 trial in allopurinol-refractory gout meets endpoints

Zafgen reports topline phase Ib data on ZGN-433 in obesity

New PET tracer [76Br]-MBBG shows promise in imaging NET-positive tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...